Life Science Investing Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Life Science Investing Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference
Life Science Investing Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
Life Science Investing Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
Life Science Investing Building a Healthier Future Together: Strengthening Cancer Care Across Africa Through Partnership
Life Science Investing U.S. Food and Drug Administration Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Life Science Investing Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
Life Science Investing Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma
Life Science Investing Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
Life Science Investing Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
Life Science Investing Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference
Life Science Investing Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
Life Science Investing Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
